ųj.

Page 1 of 2 PCTUS1/REV03

U.S. A	PPLICATION	NO. (IF KNOWN, SE	E 37 CFR 1.5)	INTERNATIONAL	APPLICAT	ON NO	1330	ATTORNEY'S	DOCKET NUMBER
		E ASSIGNED		PCT/GB97/00577				MUR-7450	
20.		lowing fees are sub						CALCULATION	S PTO USE ONLY
		L FEE (37 CFR	,,,,	` ''		***	•••		
	•		•	or JPO		\$9.	30.00		
	internationa	i preliminary exam	ination fee par	id to USPTO (37 CFF	(1.482) 	\$72	20.00		
	No internation but internation	onal preliminary ex onal search fee pai	90.00						
	Neither interinterinternational	rnational prelimina l search fee (37 CF	ry examinatio R 1.445(a)(2)	n fee (37 CFR 1.482) paid to USPTO	nor	\$1,07	70.00		
	☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)								
		ENTER A	PPROPRI	ATE BASIC FI	EE AM	OUNT	=	\$930.00	
Surcha month	arge of \$130.0 s from the ear	00 for furnishing the rliest claimed prior	e oath or decla ity date (37 C	aration later than EFR 1.492 (e)).	□ 20	0 🗆	30	\$0.00	
CL	AIMS	NUMBER	FILED	NUMBER EXT	TRA	RAT	E		
Total o	laims	14	- 20 =	0		x \$22	.00	\$0.00	
Indepe	ndent claims	1	- 3=	0		x \$82	.00	\$0.00	
Multi	ple Depender	nt Claims (check if						\$0.00	
		·	·	ABOVE CALO			_=_	\$930.00	
Reduc must a	tion of 1/2 for lso be filed (filing by small er Note 37 CFR 1.9,	tity, if applica 1.27, 1.28) (cl	able. Verified Small lack if applicable).	Entity Sta	tement		\$0.00	
					SUB'	ГОТАІ	, =	\$930.00	
Proces month	sing fee of \$1 s from the ear	30.00 for furnishir rliest claimed prior	ng the English ity date (37 C	translation later than FR 1.492 (f)).	□ 20	0 🗆	30 +	\$0.00	
				TOTAL NAT	IONAI	FEE		\$930.00	
Fee for	recording the	e enclosed assignmappropriate cover s	ent (37 CFR : heet (37 CFR	1.21(h)). The assignm 3.28, 3.31) (check it	nent must f applicab	be ole).		\$0.00	
			`	TOTAL FEES	ENCL	OSED	=	\$930.00	
				***************************************		- /		Amount to be:	\$
								refunded charged	\$
×	A -11	the amount of \$93	0.00		c :				
	Please char	ge my Deposit Acce copy of this sheet	ount No.	in the	amount of			to cover the abov	ve fees.
×				harge any fees which A duplicate copy of the				any overpayment	
NOTE 1.137(: Where an a) or (b)) mu	appropriate time st be filed and gr	limit under 3 anted to resto	37 CFR 1.494 or 1.49 ore the application to	5 has not pending	been met	, a peti	tion to revive (37 C	FR
SEND	ALL CORRE	ESPONDENCE TO):			1			
	Ratner ER & PRES	ГІА				SIGNA	URE		·
		estlakes (Berwyn)				Allan I	Zatner		
P.O.	Box 980					NAME	-mull	"" "" 	
	y Forge, Pen d States of A	nsylvania 19482-	0980						
1	407-0700/ph					19,717			
	407-0701/fax					REGIST	RATIO	N NUMBER	
ļ						01 Sep	tember	r 1998	
Ì						DATE			

300 Rec'd PCT/PTO 0 1 SEP 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

: Art Unit: Applicant: Brian Burchell Serial No.: TO BE ASSIGNED : Examiner:

Filed: HEREWITH

FOR: DRUG TRIAL ASSAY SYSTEM

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

SIR:

Prior to examination of the above-identified application, please amend the above application as follows:

IN THE SPECIFICATION:

On page 1, before the title, please insert the following:

-- This application is the U.S. National Phase of PCT International Application No. PCT/GB97/00577.--.

IN THE CLAIMS:

Please amend the claims 3, 4, 5, 6, 7, 8, 10, 11, 12, and 14 as follows:

- Use of a test as claimed in claim 1 [or 2] wherein the sample 3. 1
- is chosen from blood, buccal smear or any other sample containing DNA from 2
- the potential participants.

3

1	4. Use of a test as claim in [any of the preceding] claim[s] 1								
2	further comprising the step of eliminating participants having the genetic basis of								
3	Gilbert's Syndrome from a drugs trial.								
1	5. Use of a test as claimed in [any of] claim[s] 1 l[to 3]								
2	wherein the method comprises the further step of selecting only participants								
3	having genetic basis for Gilbert's Syndrome for a drugs trial.								
1	6. Use of a test claimed in [any of] claim[s]s 1 [to 3] further								
2	comprising the step of interpreting the results of the drugs trial in the knowledge								
3	that certain participants have Gilbert's Syndrome.								
1	7. Use of a test as claimed in [any of the preceding] claim[s] 1								
2	wherein the method comprises the steps of:								
3	a) isolating DNA from each sample,								
4	b) amplifying the DNA inner region indicating the genetic basis								
5	for Gilbert's Syndrome,								
6	c) isolating amplified DNA fragments, and								
7	d) identifying individuals having the genetic basis of Gilbert's								
8	Syndrome.								
1	8. Use of a test as claimed in [any of the preceding] claim[s] 1								
2	wherein the DNA is amplified using the polymerase chain reaction (PCR) using								
3	a radioactively labeled pair of nucleotide primers.								
1	10. Use of a test as claimed in [any of] claim[s] 7 [to 9] wherein								
2	the DNA region indicating the genetic basis of Gilbert's Syndrome is the gene								
3	encoding UDP-glucuronosyltransferase (UGT).								
1	11. Use of a test as claimed in [any of] claim[s] 7 [to 10]								
2	wherein the DNA to be amplified is in an upstream promoter region of the UGT								
3	1*1 exon 1.								
1	12. Use of a test as claimed in [any of] claim[s] 7 [to 11]								

wherein the DNA to be amplified includes the regions between -35 and -55

nucleotides at the 5' end of UGT 1*1 exon.

1	14. Primers for use of a test as claimed in [any of the preceding]
2	claim[s] 1 including primer pairs, AB or CD as follows:
3	A/B(1,5' -AAGTGAACTCCCTGCTACCTT-3',
4	B,5' -CCACTGGGATCAACAGTATCT-3') or
5	C/D (C,5'-GTCACGTGACACAGTCAAAC-3';
6	D 5' -TTTGCTCCTGCCAGAGGTT-3').

Respectfully Submitted,

Allan Ratner, Reg. No. 19,717 Attorney for Applicant

AR:sls

Dated: September 1, 1998

Suite 301 One Westlakes, Berwyn P.O. Box 980 Valley Forge, PA 19482-0980 (610) 407-0700

The Assistant Commissioner for Patents is hereby authorized to charge payment to Deposit Account No. 18-0350 of any fees associated with this communication.

EXPRESS MAIL Mailing Label Number: EL 013 897 799 US Date of Deposit: September 1, 1998

I hereby certify that this paper and fee are being deposited, under 37 C.F.R. § 1.10 and with sufficient postage, using the "Express Mail Post Office to Addressee" service of the United States Postal Service on the date indicated above and that the deposit is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, Attn: Box PCT (RO/US)

Jan Landis

09/142095

WO 97/32042

PCT/GB97/00577

300 Rec'd PCT/PTO 01 SEP 1998

"Drug Trial Assay System"

413

3

1 2

The present invention relates to drug trials, usually

1

carried out for or on behalf of pharmaceutical 4

companies. More particularly the invention relates to 5

a method for improving the efficacy of drug trials. 6

7

In the different stages of drug trials, regulatory 8

authorities in different European countries and the FDA 9

in the USA require extensive data to be provided in 10

order to approve use of the drugs. 11

12

It is important that as much information as possible is 13

available in relation to all participants who take part 14

in drug trials, from volunteers who take part in phase 15

1 trials to patients involved in stage 3 clinical 16

trials. 17

18

In particular, if certain individuals or groups of 19

individuals have severe or abnormal reactions to drug 20

administration, further studies involving that drug 21

will be in jeopardy unless the reason for the reaction 22

is realised. 23

24

The knowledge of pharmacogenetics can play an important 25

WO 97/32042

PCT/GB97/00577

1 role in understanding the impact of drug metabolism on 2 pharmacokinetics, role of receptor variants in drug response and in the selection of patient populations 3 for clinical studies. 4

5 6

7

8

9

10

11

Considerable effort has been expended in attempting to identify the pharmacogenetic basis of idiosyncratic adverse drug reactions, particularly hypersensitivity While there is clear evidence for reactions. pharmacogenetic influence on susceptibility to hypersensitivity reactions, necessary and sufficient pharamacogenetic defects have not been identified.

12 13 14

15

16

The clinical implications of genetic polymorphism in drug metabolism have been studied extensively (See Tucker GT (1994) Journal Pharamacology 46 pages 417-424).

17 18 19

25

26

28

29

30

31

32

33 34

Gilbert's Syndrome (GS) is a benign unconjugated 20 hyperbilirubinaemia occurring in the absence of structural liver disease and overt haemolysis and 21 22 characterized by episodes of mild intermittent It is part of a spectrum of familial 23 unconjugated hyperbilirubinaemias including the more 24 severe Crigler-Najjar (CN) syndromes (types 1 and 2). GS is the most common inherited disorder of hepatic bilirubin metabolism occurring in 2-12% of the 27 population and is often detected in adulthood through routine screening blood tests or the fasting associated with surgery/intercurrent illness which unmasks the hyperbilirubinaemia13. The most consistent feature in GS is a deficiency in bilirubin glucuronidation but altered metabolism of drugs has also been reported3-5. Altered rates of bilirubin production, hepatic haem production and altered hepatic uptake of bilirubin have 35 36 been reported in some GS patients2.

Ad 5

- Due to the benign nature of the syndrome and its 1 2 prevalence in the population it may be more appropriate
- to consider GS as a normal genetic variant exhibiting a 3
- reduced bilirubin glucuronidation capacity (which in 4
- 5 certain situations such as fasting, illness or
- 6 administration of drugs) could precipitate jaundice.

7

- 8 In drug trials where high levels of serum total
- 9 bilirubin is detected for certain individuals, it is
- not clear whether this is because the individuals have 10
- 11 Gilbert's Syndrome or if it because of an effect of the
- 12 drug. Whereas presently, results are explained merely
- by saying that the individuals have Gilbert's Syndrome, 13
- 14 it is suspected that in the future, it will be
- 15 necessary to prove this fact.

16

- 17 Where a jaundiced phenotype is apparent after
- 18 volunteers have been accepted for a trial and have been
- 19 subjected to five days of a strict diet, no alcohol and
- 20 no smoking, the jaundiced appearance giving an
- 21 indication that the individuals have Gilbert's
- 22 Syndrome, may cause them to be ruled out of the trials
- 23 Therefore, where approximately 250 individuals would be
- required for phase 1 trials and about 6000 patients for 24
- 25 phase 3 trials, unnecessary time and effort would have
- 26 been spent during the first 5 days of these trials and
- 27 individuals having Gilbert's Syndrome may be ill
- 28 effected.

29

- 30 Bosma et al. (New England Journal of Medicine (1995)
- 31 volume 333 Number 18) reported the genetic basis of
- 32 Gilbert's syndrome.

- 34 The present invention aims to provide a method of
- 35 improving the efficacy of drug trials in view of the
- 36 problems mentioned above.

ij

6104070701;#43

3a

- According to the present invention there is provided a 1
- method for improving the efficacy of drug trials, the 2
- method comprising the step of screening samples from 3

PCT/GB97/00577 WO 97/32042

individuals for the genetic basis of Gilbert's 1 Syndrome. 2 3 In a prefered embodiment of the invention the method 4 comprises the steps taking a sample from each potential 5 participant in a drug trial, screeing the samples for 6 the genetic basis of Gilbert's Syndrome, identifying 7 participants having the genetic basis of Gilbert's 8 9 Syndrome. 10 The sample may comprise blood, a buccal smear or any 11 other sample containing DNA from the individual to be 12 13 tested. 14 In one embodiment the method comprises the further step 15 of eliminating participants having the genetic basis of 16 Gilbert's Syndrome from the drug trial. 17 18 In an alternative embodiment, the method can comprise 19 the further step of selecting participants having the 20 genetic basis of Gilbert's syndrome and eliminating 21 others from the drug trial. 22 23 In a further alternative the results of the drug trials 24 can be interpreted in the knowledge that certain 25 participants have Gilbert's Syndrome. 26 27 Preferably the method comprises the steps of isolating 28 DNA from each sample, amplifying the DNA in a region 29 indicating the genetic basis of Gilbert's Syndrome, 30 isolating amplified DNA fragments by gel 31 electrophoresis and identifying individuals having the 32 genetic basis of Gilbert's disease. 33

34

Preferably the DNA is amplified using the polymerase 35 chain reaction (PCR) using a radioactively labelled 36

æ

į...į.

IJ

fi.j

ij

36

WO 97/32042

PCT/GB97/00577

6104070701;# 8

5

; 1- 9-98 ; 10:37 ;

```
1
      pair of nucleotide primers.
 2
      The primers are designed to prime the amplification
 3
 4
      reaction at either side of an area of the genome known
 5
      to be associated with Gilbert's Syndrome.
 б
 7
 8
      Preferably the DNA region indicating the genetic basis
      of Gilbert's Syndrome is the gene encoding UDP-
 9
10
     -qlucuronosyltransferase (UGT).
11
      By gene is meant, the non coding and coding regions and
12
      the upstream and downstream noncoding regions.
13
14
      In a preferred embodiment the DNA to be amplified is in
15
16
      an upstream promoter region of the UGT1*1 exon1.
17
      Most preferably the DNA to be amplified includes the
18
19
      region between -35 and -55 nucleotides at the 5' end of
20
      UGT1*1 exon.
21
      According to the invention there are provided suitable
22
      primers for use in a PCR reaction including primer
23
24
      pairs;
25
      A/B(A,5'-AAGTGAACTCCCTGCTACCTT-3',
26
      B,5'-CCACTGGGATCAACAGTATCT-3') or
27
      C/D (C,5'-GTCACGTGACACAGTCAAAC-3';
28
      D 5'-TTTGCTCCTGCCAGAGGTT-3')
29
30
      The invention further comprises a kit for screeing
31
      individuals for participation in drug trials, the kit
32
      comprising primers for amplifying DNA in a region of
33
      the genome indicating the genetic basis of Gilbert's
34
35
      Syndrome.
```

RECTIFIED SHEET (RULE 91)
ISA/EP

WO 97/32042 PCT/GB97/00577

5

MURGITROYD & CO. →

1	Using pri	mer s	sequences	as d	escribed	d herein	n, DNA	can	be
2	amplified	and	analysed	usin	g among	others	any c	f th	e
3	following	prot	cocols;						

4

5 Protocol 1 Radioactive method

б

7 Extract DNA from Buccal Cells or 3ml Blood. ı.

8 9

- Choose primers from either side of the "TATA" box 10 2. region of UGT1*1 exon1 regulatory sequence. 11
- Freshly end label one primer with $[\gamma]^{11}\alpha]$ -ATP (40) 12

13 min).

14

Amplifying a small region up to 100 bp in length 15 3. by PCR (2h). 16

17

18 4. Apply to 6% PAG denaturing gel (preparation, loading, run time, 4h). 19

20

Expose (-70°C) wet gel to autoradiographic film 21 5. 22 (15 min).

23

24 This method takes about 7h to complete. Polymorphisms only observed in TATA box non coding region todate. 25

26

- 27 Protocol 2
- 28 Alternative Radioactive Method: Solid Phase
- Minisequencing 29

30

31 Extract DNA (as above) 1.

32

33 2. Prepare primers biotinylating one

34

Amplify DNA by PCR using primers 35 3.

ğ.,4

¥...‡

413

PCT/GB97/00577 WO 97/32042

7

Captive biotinylated PCR products on streptavidin 4. Į coated support and deactive. 2 3 Carry out primer extension reaction sequencing. 5. 4

5

6 Protocol 3

7 Non-Radioactive Methods:

8

- (a) Analysis by Single Strand Conformational 9
- Polymorphism (SSCP) 10 11 ı. Extract DNA (as above).

12

13 14

Amplify a small region up to 100 bp in length by 15 З.

Choose primers either side of the TATA Box.

PCR (2H). 16

2.

17 Denature and place on ice (15 min). 4.

18

- 5. Load onto a non-denaturing PAG gel, 19
- (preparation/load/run time, 4h). 20

21

Stain with Ethidium bromide or silver nitrate (30 22 6.

23 mm).

24

- This method still takes about 7h to complete, but is 25
- potentially slightly cheaper since there is no 26
- radioactivity or autoradiography. 27

28

- This method could be done on an automated DNA sequencer 29
- from stage 5, if primers are tagged with chromophores 30
- in PCR stages 2 and 3. Result would then be read 31
- 32 automatically.

33

Oligonucleotide Assay Hybridization 34

35

36 Extract DNA (as above). 1.

inia Enia

£.,‡

Ĩij,

WO 97/32042

PCT/GB97/00577

8

Choose primers and amplify DNA by PCR up to 100 bp
 in length.

3 4

Apply DNA to plastic grids.

5

6 4. Screen bound DNA samples with specific DNA probes
7 for TA₅, TA₆, TA₇ tagged with different
8 coloured/fluorescent chromphores.

9

10 5. Read ouput automatically for experimental protocols.

12

13 References

14

15 Monaghan G et al. Lancet (1996) 347 578-581.

16

- 17 "Detection of polymorphisms of human DNA by gel
- 18 electrophoresis or single-strand conformational
- 19 polymorphisms"." Orita M et al. Proc Matl Acad Sci
- 20 (USA) (1989) 86 2766-2700.

- 22 "Assays of complementary oligonucleotides for analysing
- 23 Hybridization behaviour of Nucleic Acids". Southern E
- 24 M. Nuc Acids Res (1194) 22 1368+1373.

CO. → 6104070701;#12

then the state of the state of

ğ.,,k

ļ..L

£...‡

fü

35

36

WO 97/32042 PCT/GB97/00577

9

The basis of the invention is illustrated in the 1 following example with reference to the accompanying 2 figures wherein: 3 5 Figure 1 illustrates genotypes at the TATA box sequence 6 upstream of the UGT1*1 exon 1 determined by direct 7 sequencing and radioactive PCR. 8 9 Figure 2 illustrates serum total bilirubin (μmol/1) 10 plotted against UGT1*1 exon 1 genotype. 11 Figure 3 illustrates segregation of the 7/7 genotype 12 13 with elevated serum total bilirubin concentration in a family with GS. 14 15 Figure 4 illustrates the 5' sequence of the UGT1*1 exon 16 17 1 and the position of the primers with respect to the 18 UGT gene. 19 20 Example 21 22 We have examined the variation in the serum total bilirubin (STB) concentration in a representative group 23 24 of the Eastern Scottish population (drug-free, alcohol-25 free non-smokers) in relation to genotype at the UDP-26 glucuronosyltransferase subfamily 1 (UGT1) locus. 27 Subjects with the 77/7 genotype in this population have a significantly higher STB than those with 6/7 or 6/6 28 29 genotypes. Of 14 control subjects who underwent a 24 30 hour fast to establish whether they had Gilbert Syndrome (GS), only 7/77 subjects had GS. In addition, 31 one confirmed GS patient, two recurrent jaundice 32 patients and 9 clinically diagnosed GS patients had the 33 7/7 genotype. Segregation of the 7/7 genotype with 34

elevated STB concentration has also been demonstrated in a family of 4 Gilbert members. This incidence of

WO 97/32042

PCT/GB97/00577

10

the 7/7 genotype in the population is 10-13%. Here, we 1 demonstrate a correlation between variation in the 2 human STB concentration and genotype at a TATA sequence 3 upstream of the UGT1*1 exon 1 and that the 7/7 genotype 4 is diagnostic for GS. 5 6 The inheritance of GS has been described as autosomal 7 dominant or autosomal dominant with incomplete 8 penetrance based on biochemical analysis. More recent 9 reports have suggested that the mildly affected 10 (Gilbert) members of families in which CN type 2 (CN-2) 11 occurs are heterozygous for mutations in the UDE 12 glucuronosyltransferase subfamily 1 (UGT1) gene which 13 cause CN-2 in the homozygous state. The inheritance of 14 GS in these families is autosomal dominant while CN-2 15 is autosomal recessive 7-11. However, the incidence of 16 rare and the frequency CN-2 in the population is 17 of alleles causing CN-2 would not be sufficient to 18 explain the population incidence of GS. 19 20 An abstract by Bosma et al 12 suggested a correlation 21 between homozygosity for a 2bp insertion in the TATA 22 box upstream of UGT1*1 exon 1 and GS (no mutations were 23 found in the coding sequence of the UGT1*1 gene). In 24 this report we demonstrate that the primary genetic 25 factor contributing to the variation in the serum total 26 bilirubin (STB) concentration in the Eastern Scottish 27 population is the sequence variation reported by Bosma 28 et al¹². In addition, we show that the 7/7 genotype --29 associated with GS and occurs in 10-13% of the 30 population. 31 32 Methods 33 Patients and Controls 34 Whole blood (3ml) was collected into EDTA(K3) 35 Vacutainer tubes (Becton Dickinson) from one confirmed 36

WO 97/32042

PCT/GB97/00577

11

male Gilbert patient (diagnosed following a 48 hour 1 restricted diet(3), two female patients with recurrent 2 jaundice/associated elevated STB (29-42 μmol/1) and 9 3 4 (1 female, 8 male) clinically diagnosed GS subjects 5 (persistent elevation of the STB amidst normal liver 6 function tests.) The patients were aged 22-45 years. 7 8 77 non-smoking residents selected at random from the 9 Tayside/Fife region of Scotland (39 females aged 19-58 10 years, mean 32.41± 10.94; 38 males aged 23-57, means 35.58 \pm 9.04) participated in this study. Whole blood 11 12 (9ml) was collected 8-10am) into EDTA(K3) Vacutainer tubes (Becton Dickinson) for DNA extraction and SST 13 Vacutainer tubes (Becton Dickinson) for biochemical 14 15 investigations. The subjects had not taken any 16 medication or alcohol in the previous 5-7 days and had 17 fasted overnight (12 hours). 14 controls subsequently 18 underwent further biochemical tests (following a 3 day abstinence from alcohol) before and after a 24 hour 19 400-calorie dieti4 to determine if they had GS. All 20 patients/controls were fully informed of the study and 21 22 gave consent for their blood to be used in this study. 23 24 Biochemistry and DNA Extraction 25 26 The following biochemical tests were performed on 27 control blood samples; alanine aminostransferase, 28 albumin, alkaline phosphatase, amylase, STB, 29 cholesterol, creatinine, creatine kinase, free thyroxine, gamma-glutamyl-transferase, glucose, HDL-30 31 cholesterol, HDL-cholesterol/total cholesterol, iron, 32 lactate dehydrogenase, percentage of saturated 33 transferrin (PSAT), proteins, serum angiotensin

converting enzyme, thyroid stimulating hormone,

also had pre- and post-fasting (24 hour) alanine

transferrin, triglycerides, urate, urea. 14 controls

> 34 35

36

ij

Ŧij.

ij

PCT/GB97/00577

12

aminostransferase, albumin, alkaline phosphatase, STB 1 and urate measured. DNA was prepared using the Nucleon 2 II Genomic DNA Extraction Kit (Scotlab) according to 3 manufacturer's instructions. 4 5 6 Genotyping 7 Polymerase Chain Reaction 8 9 Primer pairs A/B (A, 5'-AAGTGAACTCCCTGCTACCTT-3'; B, 10 5'-CCACTGGGATCAACAGTATCT-3') or C/D (C,5'-11 GTCACGTGACACAGTCAAAC-3';D, 5'-TTTGCTCCTGCCAGAGGTT-3') 12 flanking the TATA box sequence upstream of the UGT[*1 1*1 13 exon 1 were used to amplify fragments of 253-255bp and 14 98-100bp, respectively. Amplifications (50 μ 1) were 15 performed in 0.2mM of each deoxynucleoside triphosphate 16 (datp, dctp, dgtp, dttp), 50mM KCI, 10mM Tris.HCl (pH 17 9.0 at 25 C), 0.1% Triton X-100, 1.5mM MgCl₂, 0.25μM of 18 each primer, 1 Unit of Taq Polymerase (Promega) and 19 human DNA $(0.25-0.5\mu g)$. The polymerase chain reaction 20 (PCR) conditions using the Perkin-Elmer Cetus DNA 21 Thermal Cycler were: 95'C 5 min followed by 30 cycles 22 of 95° 30 sec, 58°C 40 sec, 72°C40 sec. 23 24 25 Direct Sequencing 26 Amplification was confirmed prior to direct sequencing 27 by agarose gel electrophoresis. Sequencing was 28 performed using $\{\alpha^{-35}S\}$ -dATP (NEN Dupont) with the USB 29 Sequenase PCR Product Sequencing Kit according to 30 manufacturer's instructions. Sequenced products were 31 resolved on 6% denaturing polyacrylamide gels. The 32 dried gels were exposed overnight to autoradiographic 33 film prior to developing. 34

Radioactive PCR 36

ļ...i.

N

40

36

WO 97/32042

PCT/GB97/00577

13

1 Amplification was performed as above using primer pair C/D except that 2.5 pmol of primer C was radioactively 2 5' end-labelled with 2.5 μ Ci of $(\gamma^{-12}P)$ -ATP (NEN Dupont) 3 prior to amplification. Products were resolved on 6% 4 denaturing polyacrylamide gels and the wet gels exposed 5 to autoradiographic film (-70°C 15 min) and the 6 autoradiographs developed. 7 8 9 Statistics 10 A t-test was used to determine if there was a 11 significant age difference between males and females. 12 χ^2 analysis was used to assess any difference in the 13 14 distribution of the 6/6, 6/7 and 7/7 genotypes in males and females and also to determine if the 7/7 subjects 15 from the 24 hour fasted group had STB elevated into the 16 range diagnostic for GS14. An analysis of variance was 17 performed to compare mean STB in males and females 18 within each genotype group. A non-parametric test, the 19 Mann-Whitney U-Wilcoxon Rank Sum W Test was used to 20 determine whether there was a significant difference in 21 22 mean STB between males and females (irrespective of genotype). Correlations and significance tests were 23 performed for STB versus PSAT and STB versus iron. A 24 25 probability (p) of (0.05 was accepted as significant. 26 27 Results 28 In Figure 1 a photographic representation of the sense 29 30 DNA sequences obtained by PCR/direct sequencing of DNA samples having the genotypes 6/6, 6/7 and 7/7 is shown. 31 32 The common allele, (TA), TAA, is denoted by "5" while the rarer allele, (TA), TAA, is denoted by "7". Below each 33 34 sequence is an overexposed photographic representation of the 98 to 100bp resolved fragments amplified using 35

primer pair C/D which flank the TATA sequence upstream

PCT/GB97/00577 WO 97/32042

14

of the UGT1*1 exon 1. The additional fragments of 99 1 and 101 bases are thought to be artifacts of the PCR 2 process where there is non specified addition of an 3 extra nucleotide to the 3' end of the amplified 4 product21. | Figures 1b illustrates results after testing 5 a range of unknown individuals. 6 7 In Figure 2 males (M) and females (F) are plotted 8 separately | Each circle/square represents the result 9 of a single control subject. The squares indicate the 10 14 controls who also underwent the 24 hour restricted 11 diet (see Methods). The filled circles/squares 12 represent those who had a lower than normal PSAT (≤ 13 22%) while the half-tone circles represent those who 14 had a higher than normal PSAT (≥ 55%). The mean STB 15 concentrations (indicated by the horizontal lines) for 16 males were $13.24 \pm 3.88 (6/6)$, $13.94 \pm 6.1 (6/7)$ 17 including control h or 12.69 ± 3.34 excluding control 18 h, 29 \pm 14 45 (7/7) and for females were 9 \pm 3.62 19 (6/6), 12.2 ± 3.53 (6/7), 21.6 ± 7.8 (7/7). The 20 encircled result is from control h (discussed in the 21 22 text). 23 In Figure 3 males and females are represented by 24 squares and circles, respectively. Filled and half-25 filled circles/squares indicate the genotypes 7/7 and 26 6/7, respectively. The numbers in parentheses below 27 each member of the pedigree are the STB concentrations 28 measured after a 15 hour fast and 7 day abstinence from 29 alcohol. All family members were non smokers who were 30 not taking any medication when the biochemical tests 31 were performed. Elevated STB are underlined. 32 Individual members of each generation (I or II) are 33 denoted by the numbers 1-4 above each circle/square. 34 Generation III have not yet been tested. 35

##

36

1.3

WO 97/32042

PCT/GB97/00577

15

There was no significant age difference between males 1 2 and females (t = -1.38, p = 0.17). Genotypes were determined initially by amplification/sequencing and 3 later by the radioactive PCR approach. Individuals 4 5 homozygous for the common allele, hetrozygous or homozygous for the rarer allele have the genotypes 6/6, 6 6/7 and 7/7, respective. 12 DNA samples (2 of 6/6, 3 7 8 of 6/7 and 4 of 7/7) were analysed by both methods and 9 genotype results were identical (see Figure 1). 10 Genotype frequencies in male controls were 6/6 (44.74%, 11 6/7 (44.74%), 7/7 (10.52%) and in female controls were 12 6/6 (35.9%), 6/7 (51.3%), 7/7 (12.8%). There was no 13 significant difference between the genotype proportions 14 in the two groups ($\chi^2 = 0.6$ at 2 df, p = 0.7). Control 15 h (encircled in Figure 2) had a STB which was 2.4 SD 16 above the mean STB for that group (mean calculated 17 including control h). The results for control h were 18 repeatable and he is currently being investigated to 19 exclude haemochromatosis. Comparison of mean STB in 20 males and females revealed that females have a 21 significantly lower concentration than males (p = 0.031 22 including control h; p + 0.0458 excluding control h). 23 24 There was a strong correlation between genotype and mean STB concentration within the control group (p (25 0.001) irrespective of whether control h was included 26 and there was a significant difference in mean STB 27 28 between males and females of the same genotype (p (29 0.05) irrespective of whether control h was included (see Figure 2). All patients studied had the 7/7 30 31 genotype. 32 Correlations between STB/PSAT (r = 0.4113, p = 33 0.001) (see Figure 2) and STB/iron females (p = 0.001) 34 than males (p = 0.01) but when control h is excluded 35 there was no significant correlation in males.

WO 97/32042

PCT/GB97/00577

16

1	The STB concentrations of control who underwent the 24
2	hour restricted diet (see Methods) are shown in matter
3	1. The normal fasting response is a small rise in the
4	base-line STB (not exceeding a final concentration of
5	25μmol/1) most of which is unconjugated while GS
6	patients have a lone biochemical feature a raised STB
7	()25 μ mo1/1 but (50 μ mo1/1) most of which is
8	unconjugated4. The 6/6 and 6/7 controls had post-
9	fasting STB of ≤23μmol/1 while all 7/7 controls were
10	≥31µmo1/1. Other liver function tests were within
11	acceptable ranges for the age and sex of the subjects.
12	The 7/7 genotype correlates with a fasted STB (24
13	hour) within the range diagnostic for GS14 (p (
14	0.01) (see Table 1). In addition, the 7/7 genotype
15	segregates with elevated STB concentration in a family
16	with 4 GS members (Figures 3).
17	
18	Table 1 shows a comparison of the UGT1*1 exon 1
19	genotype with elevation in the serum total bilirubin
20	after a 24 hour 400-calorie restricted diet14.
21	•
22	An elevation of the fasting STB to a final
23	concentration in the range 25-50 mmol/l is considered to
24	be diagnostic for GS14. The 7/7 subject denoted by *
25	has a fasting and non-fasting STB of) 50 mmol/1 but
26	this value is within a range considered by others to

conform to a diagnosis of GS7-11.

WO 97/32042

PCT/GB97/00577

17

Table 1

		24 hou	r fast	
Genotype	Sex	Before	After	Fasting bilirubin >25 & <50µmol/l
6/6	M M M	8 9 12	17 19 15	NO NO NO
6/7	F F F M M	8 9 11 12 8 15	17 13 12 17 10 23 18	NO NO NO NO NO NO
7/7	F F M M	9 12 19 62	34 34 31 96	Yes Yes Yes No*

Discussion

1 2 3

4

5

6

7

8

9

10

A few recent reports claim to have identified the genetic cause of GS10-12. Clinical diagnosis of GS is often based on a consistent midly elevated non-fasting STB ()17 μ mo1/1) as the sole abnormal liver function test, intermittent jaundice or both. The diagnosis can be confirmed by elevation of the STB to $25-50\mu\text{mol/1}$ after a 24 hour 400-calorie diet14 or by elevation of the unconjugated bilirubin by) 90% within 48 hours of commencing a 400 calorie diet13.

11 12 13

14

15

16

17

18

Sato's research group recently reported the occurrence of 7 different heteroxygous missence mutations in unrelated Gilbert patients (most of the mutations have been found in the homozygous state in affected members of CN families), however, the non-fasted STB for thepatients were \rangle 52 μ mol/1 (with the exception of one,

ŧij.

H H Man

Ę.,;

41,5

Į.i.L

£...}

ŧij. đij.

35

36

WO 97/32042

PCT/GB97/00577

18

31µmol/1) 10.12. These non-fasted STB concentrations 1 already exceed the diagnostic range for GS14, hence 2 these patients have a more severe form of 3 hyperbilirubinaemia than those studied in this report, 4 while those in the Bosma et al12 abstract had STB 5 concentrations similar to those studied here. 6 7 The example herein shows that the variation in the 8 levels after an overnight fast (and in the absence of 9 exposure to known inducers of the UGT1*1 isoform in GS, 10 such as alcohol 15 and drugs16) a representative group 11 of the Eastern Scottish population is primarily due to 12 (or associated with) the TATA box sequence variation 13 reported by Bosma et al12. In agreement with previous 14 work females have a significantly lower mean STB 15 concentration than males 17-18. 16 17 Individuals with the 7/7 genotype in the population 18 have GS (see Table 1). One of the 7/7 controls 19 indicated in Table 1 had a non-fasting STB similar to 20 those reported for heterozygous carriers of CN-2 21 22 mutations "" which suggests that this subject may also be a carrier of a CN-2 mutation, alternatively, the 23 very elevated bilirubin in this patient may be due to 24 the coexistence of Reavon's Syndrome (characterized by 25 a collection of abnormal biochemical results which are 26 risk factors for coronary heart disease) 19. 27 28 We have found that 10-13% of the Eastern Scottish 29 population have the genotype associated with mild GS. 30 None of the Gilbert subjects from the control 31 population were aware that they had an underlying 32 metabolic defect in glucuronidation with testifies to 33 its benign nature. Three 7/7 controls had STB 34 concentrations comparable to mean levels observed in

heterozygotes, however, they also had a lower than

WO 97/32042

PCT/GB97/00577

19

1 normal PSAT (≤22%) (see Figure 2). The observed 2 correlation between STB and PSAT (p = 0.001) (Figure 2) and STB and iron (females p = 0.001 and males p = 0.013 including control h) indicates that other genetic and 4 5 environmental factors affecting the serum PSAT and iron 6 values will in turn affect the STB concentration. 7 8 From the data presented here and previous reports it 9 seems clear that there are mild and more severe forms 10 The milder form (fasted STB 25-50µmol/1) is 11 either caused by (or is associated with) a homozygous 12 2bp insertion at the TATA sequence upstream of the 13 UGT1*1 exon 1 (autosomal recessive inheritance) while the rarer more severe dominantly inherited forms 14 identified to date 1-11 (non-fasted STB) 50 mmol/l are due 15 16 to heterozygosity for a mutation in the coding region 17 of the UGT1*1 gene which in its homozygous state causes 18 CN-2. The particular genetic abnormality causing GS in 19 a patient will have implications for genetic 20 counselling as the dominantly inherited form of two GS 21 patients could result in offspring with CN-2, whereas 22 the recessive form in one or both GS patients would 23 have less serious implications. It is important to 24 discriminate between the two forms and provide suitable 25 genetic counselling for such couples. The rapid DNA 26 test presented here (less than 1 day for extracted DNA) 27 carried out in addition to biochemical tests following 28 a 12 hour overnight fast (without prior alcohol or drug 29 intake would permit such a diagnosis. The compliance 30 rate for the current 24 and 48 hour restricted diet tests for GSB-16 is debatable and hence the overnight 31 32 fast has obvious advantages and only one blood sample 33 or a buccal smear is required (for genetic and 34 biochemical analysis) in contrast to the 2-3 blood 35 samplings required for the 24 and 48 hour tests. This 36 approach to GS testing would be cost effective in terms

ŧij. Į.i. fij ij į.,i. ģ.,;<u>.</u> TI, 13 M

đij.

WO 97/32042

PCT/GB97/00577

20

of fewer patient return visits to clinics and in 1 identifying couples at risk of having children with 2 CN-2. 3 4 In addition, the recent finding of an increased 5 bioactivation of acetominophen (a commonly used 6 analgesic which is eliminated primarily by 7 glucuronidation) in GS patients indicates the greater 8 potential for drug toxicity in these patients if 9 administered drugs which are also conjugated by UGT1 10 isoforms³. In fact, ethinylestradiol (EE2) has recently 11 been shown to be primarily glucuronidated by the UGL- - 1 12 isoform in man and hence this could have implications 13 for female Gilbert patients taking the oral 14 contraceptive who are then more predisposed to 15 developing jaundice. 16 17 18 The tests outlined herein have obvious implications for 19 setting up drug trials in understanding unusual results 20 in ruling out individuals who may be adversely affected 21 by the drugs or in positively choosing these 22 individuals to determine the effects of particular 23

drugs on hyperbilirubinaemia.

25

36

PCT/GB97/00577

21

1 References 2 3 Fevery, J. Pathogenesis of Gilbert Syndrome. Eur. 1 J. Clin. Invest. 1981;11; 417-418. 4 5 Watson, K.J.R. and Gollan, J.L. Gilbert's 2. 6 Syndrome. Bailliere's Clinical Gastroenterology 7 1989; 3: 337-355. 8 9 De Morais, S.M.F., Uetrecht, J.P. and Wells, P.G. 10 3. Decreased glucuronidation and increased 11 bioactivation of acetaminophen in Gilbert's 12 Syndrome. Gastroenterology 1992; 102: 577-586. 13 14 Carulli, N., Ponz de Leon, M., Mauro, E., Manenti, 4. 15 F and Ferrari, A. Alteration of drug metabolism in 16 Gilbert's Syndrome. Gut 1976; 17: 581-587. 17 18 Macklon, A.F., Savage, R.L. and Rawlins, M.D. 5. 19 Gilbert Syndrome and drug metabolism. Clin. 20 21 Pharmacokinetics 1979; 4: 223-232. 22 6. Thompson, R.PH.H. Genetic transmission of 23 Gilbert's Syndrome in "Familial 24 Hyperbilirubinaemia", (Ed. L. Okoliosanyi), John 25 Wiley & Sons Ltd; 91-97. 26 27 Gollan, J.L. Huang, S.N., Billing, B. and 28 7. Sherlock, S. Prolonged survival in three brothers 29 with severe type 2 Crigler-Najjar Syndrome. 30 Gastroenterology 1975; 68: 1543-1555. 31 32 Moghrabi, N., Clarke, D.J., Boxer, M. and 33 8. Burchell, B. Identification of an A-to-G missence 34

mutation in exon 2 of the UGT1 gene complex that

causes Crigler-Najjar Syndrome type 2. Genomics

1ij

WO 97/32042

PCT/GB97/00577

22 1993; 18: 171-173. 1 2 Moghrabi, N.N. Molecular Genetic Analysis of the 3 9. Human Phenol and Bilirubin UDP-4 Glucuronosyltransferase Gene Complex and 5 Associated Disease Syndromes. PhD thesis 1994. 6 University of Dundee, Dundee, Scotland. 7 8 10. Aono, S., Adachi, Y., Uyama, E., Yamada, Y., 9 Keino, H., Nanno, T., Koiwai, O. and Sato, H. 10 Analysis of genes for bilirubin UDP-11 glucuronosyltransferase in Gilbert's Syndrome, 12 Lancet 1995; 345: 958-959. 13 14 Koiwai, O., Nishizawa, M., Hasada, K., Aono, S., 15 11. Adachi, Y., Mamiya, N. and Sato, H. Koiwai, O., 16 Nishizawa, M., Hasada, K., Aono, S., Adachi, Y., 17 Mamiya, N. and Sato, H. Gilbert's Syndrome is 18 caused by a heterozygous missence mutation in the 19 gene for bilirubin UDP-glucuronosyltransferase. 20 Hum. Molec. Genet. 1995; 4: 1183-1186. 21 22 Bosma, P., Goldhoorn, B., Bakker, C., Out, T., Rov 23 12. Chowdhury, J., Roy Chowdhury, N., Oostra, B., 24 Lindhout, D., Michiels, J., Jansen, P., Tytgat, G. 25 and Qude Elferink, R. Presence of an additional TA 26 in the TATAA box of B- UGT1 correlates with 27 Gilbert Syndrome. Hepatology October 1994; 28 Abstract 680: 226A. 29 30 Owens, D. and Sherlock, S. Diagnosis of Gilbert's 31 13. Syndrome: role of reduced calorie intake test. 32 Br. Med.J. 1973; 3: 559~563. 33

34

Lascelles, P.T. and Donaldson, D. Calorie 35 14. restriction test in "Diagnostic Function Tests in 36

253.

WO 97/32042

PCT/GB97/00577

23 Chemical Pathology" Kluwer Academic Publishers 1 2 1989: 24-25. 3 Ideo, G., De Franchis, R., Del Ninno, E. and 4 15. Dioguardi, N. Ethanol increases liver uridine-5 diphosphate-glucuronosyltransferase. Experientia 6 1971; 27: 24-25. 7 8 16. Sutherland, L.T., Ebner, T. and Burchell, B. 9 Expression of UDF-Glucuronosyltransferases (UGT) 1 10 family in human liver and kidney. Biochem. 11 Pharmacol. 1993; 45: 295-301. 12 13 17. Owens, D. and Evans, J. Population studies on 14 Gilbert Syndrome. J. Med. Genet. 1975;12: 152-15 16 156. 17 Bailey, A., Robinson, D. and Dawson, A.M. Does 18 Gilbert's disease? Lancet 1977; 1: 931-933. 19 20 Reaven, G.M. Syndrome X: 6 years later. J. 21 Intern. Med. 1994; 236: 13-22. 22 23 Ebner. T., Remmel, R.P. and Burchell, B. Human 24 20. bilirubin UDP-glucuronosyltransferase catalyses 25 the glucuronidation of ethinylestradiol. Molec. 26 Pharmacol. 1993; 43: 649-654. 27 28 Edwards, A., Hammond, H.A., Jin, L., Caskey, C.T. 29 and Chakraborty, R. Genetic variation at five 30 trimeric and tetrameric tandem repeat loci in four 31 human population groups. Genomics 1992; 12: 241-32

			•
1	CLAI	MS	
2			
3	1.	Use	of a test for detecting the genetic basis of
4		Gilb	pert's Syndrome in a method to improve the
5		effi	dacy of drug trials, the method comprising
6		scre	ening samples from potential participants for
7		the	basis of Gilbert's Syndrome and eliminating or
8		incl	uding potential participants in a drug trial
9		in t	he knowledge of them possessing or not
10		poss	essing the genetic basis of Gilbert's
11		Synd	zome.
12			
13	2.	Use	of a test as claimed in claim 1 wherein the
14		meth	od comprise the steps of:
15			
16		a)	taking a sample from each potential
17			participant in a drug trial,
18			
19		b)	screening the samples for the genetic basis
20			of Gilbert's Syndrome,
21			
22		c)	identifying participants having the genetic
23			basis of Gilbert's Syndrome, and
24			

25

26

d)

29 3 Use of a test as claimed in claim 1 or 2 wherein 30 the sample is chosen from blood, buccal smear or 31 any other sample containing DNA from the potential 32 participants.

proceeding with drugs trials in the knowledge

the genetic basis of Gilbert's Syndrome.

of participants possessing or not possessing

33 34

35

36

4. Use of a test as claimed in any of the preceding claims further comprising the step of eliminating participants having the genetic basis of Gilbert's

6104070701;#45

1		Syndrome from a drugs trial.
2		
3	5.	Use of a test as claimed in any of claims 1 to 3
4		where in the method comprises the further step of
5		selecting only participants having genetic basis
6		for Gilbert's Syndrome for a drugs trial.
7		
8	6.	Use of a test as claimed in any of claims 1 to 3
9		further comprising the step of interpreting the
10		results of the drugs trial in the knowledge that
11		certain participants have Gilbert's Syndrome.
12		
13	7.	Use of a test as claimed in any of the preceding
14		claims wherein the method comprises the steps of:
15		
16		a) isolating DNA from each sample,
17		
18		b) amplifying the DNA inner region indicating
19		the genetic basis for Gilbert's Syndrome,
20	•	
21		c) isolating amplified DNA fragments, and
22		
23		 d) identifying individuals having the genetic
24		basis of Gilbert's Syndrome.
25		
26	8.	Use of a test as claimed in any of the preceding
27		claims wherein the DNA is amplified using the
28		polymerase chain reaction (PCR) using a
29		radioactively labelled pair of nucleotide primers.
30		
31	10.	Use of a test as claimed in any of claims 7 to 9
32		wherein the DNA region indicating the genetic
33		basis of Gilbert's Syndrome is the gene encoding
34		UDP-glucuronosyltransferase (UGT).
35		
36	11.	Use of a test as claimed in any of claims 7 to 10


6104070701;#46

1		wherein the DNA to be amplified is in an upstream
2		promoter region of the UGT 1*1 exon 1.
3		
4	12.	Use of a test as claimed in any of claims 7 to 11
5		wherein the DNA to be amplified includes the
6		regions between -35 and -55 nucleotides at the 5'
7		end of UGT 1*1 exon.
8		
9	13.	A kit for screening individuals participation in
10		drug trials, the kit comprising primers for
11		amplifying DNA in the region of the genome
12		indicating the genetic basis of Gilbert's
13		Syndrome.
14		
15	14.	Primers for use of a test as claimed in any of the
16		preceding claims including primer pairs, AB or CD
17		as follows:
18		
19		A/B(A,5'-AAGTGAACTCCCTGCTACCTT-3',
20		B,5'-CCACTGGGATCAACAGTATCT-3') or
21		C/D (C,5'-GTCACGTGACACAGTCAAAC-3';
22		D 5'-TTTGCTCCTGCCAGAGGTT-3').

PCT/GB97/00577

WO 97/32042

1/4





Fre 1b


SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

WO 97/32042

PCT/GP^=**

Showing Segregation of the Gilbert Phenotype with 3/4 the (TA), TAA/(TA), TAA Genotype.



I, II, III - generations in family *= genetic and biochemical data similar

male

□ homozygotes for the (TA), TAA allele

female

heterozygotes for the (TA), TAA and

(TA)6 TĂĂ alleles


(13) = total serum bilirubin

(18-25) = elevated total serum bilirubin

And the same

WO 97/32042

PCT/GB97/00577





SUBSTITUTE SHEET (RULE 26)

Declaration and Power of Attorney For Patent Application English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

DRUG TRIAL ASSAY SYSTEM,

	***************************************			44 # 11 '		
the specification	of which is	eattachad he	refo uniess	the tollowing	צו אסמינ	cnecked.
ine specification	OI MITICEL 19	attachicanic	i clo ai noco		J	

was filed on <u>03 March 1997</u> as

United States Application Number or PCT International Application Number PCT/GB97/00577 and was amended on 03 April 1998 and 01 September 1998 (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Prior Foreign	Application(s)
---------------	----------------

Priority Not Claimed

<u>9604480.5</u>

GB

01 March 1996 (01.03.96)

(Number)

(Country)

(Day/Month/Year Filed)

9605598.3

GB

16 March 1996 (16.03.96)

(Number)

(Country)

(Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

	*	۶	100 DL		
(Application Number)	- (Filing Date)	(Status - pater	ited, pending, abandoned)	
(Application Number)	- (Filing Date)	(Status - pater	nted, pending, abandoned)	
POWER OF AT agent(s) to proseconnected therever	ecute this applic	a named inventor, cation and transact	I hereby appoir t all business in	nt the following atto the Patent and Tra	rney(s) and/or demark Office
Paul F. Prestia Allan Ratner Andrew L. Ney Kenneth N. Nigon Kevin R. Casey Benjamin E. Leace James C. Simmons	Reg.No. 23,031 Reg.No. 19,717 Reg.No. 20,300 Reg.No. 31,549 Reg.No. 32,117 Reg.No. 33,412 Reg.No. 24,842	Lawrence E. Ashery Robert L. Andersen Christopher R. Lewis Louis W. Beardell, Jr. Rocco L. Adornato Jacques L. Etkowicz Eric A. Dichter	Reg. No. 34,515 Reg. No. 25,771 Reg. No. 36,201 Reg. No. 40,506 Reg. No. 40,480 Reg. No. 41,738 Reg. No. 41,708	Mark J. Marcelli Joshua L. Cohen Christopher J. Dervishian Jack J. Jankovitz	Reg.No. 36,593 Reg.No. 38,040 Reg.No. 42,480 Reg.No. 42,690
Address all correst Ratner & Presti Address all teleph	a, Suite 301, On	llan Ratner e Westlakes, Berwyr an Ratner at (610) 4	n, P.O. Box 980, ' 07-0700.	Valley Forge, PA 194	<u>82-0980</u>
statements mad were made with	e on informatior the knowledge conment, or both	n and belief are bel that willful false n. under Section 10	lieved to be true statements and 201 of Title 18 d	n knowledge are true; and further that the like so made of the United States cation or any patent is	ese statements are punishable Code and that
Inventor's signature Residence <u>8 Douga</u> Citizenship <u>GB</u> Post Office Address	N/S Y BB	e DD6 9 JB GREAT BR	Kell	Date	9/98_
Full name of second	joint inventor, if any	(given name, family nam	ne)		
Residence Citizenship Post Office Address					
Additional inv	ventors are being na	med on separately numb	ered sheets attached	hereto.	

Declaration and Power of Attorney For Patent Application **English Language Déclaration**

As a below named inventor, I hereby declare that
--

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

DRUG TRIAL ASSAY SYSTEM,

	O LICHTET							
ho c	pecification	of which	is attached	hereto	unless the	following	box is	checked:
11169	pedilication	OI WITHOUT	is allaonou	1101010	arnoss are			

was filed on 03 March 1997 as

United States Application Number or PCT International Application Number PCT/GB97/00577 and was amended on 03 April 1998 and 01 September 1998 (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Not Claimed

9604480.5

GB

01 March 1996 (01.03.96)

(Number)

(Country)

(Day/Month/Year Filed)

9605598.3

GB

16 March 1996 (16.03.96)

(Number)

(Country)

(Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

	the state of the	:	:	No.
		:	:	135115
	a a	:	:	
	22		:	2
			:	Table of the last
		:	:	
	1		:	111.11
	in H Heart Heart Lat's small		:	
	3			
	1			
	and the	:		
	50.00	:	:	0
	a State Chairman of Bank	-		de strange and
-	W. Bent			March -
	-			_

(Application Number)		(Filing Date) (Status - patented, p		nted, pending, abandoned)	pending, abandoned)			
(Application Number)		(Filing Date)	(Status - patented, pending, abandoned)					
POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:								
Paul F. Prestia Allan Ratner Andrew L. Ney Kenneth N. Nigon Kevin R. Casey Benjamin E. Leace James C. Simmons	Reg.No. 23,031 Reg.No. 19,717 Reg.No. 20,300 Reg.No. 31,549 Reg.No. 32,117 Reg.No. 33,412 Reg.No. 24,842	Lawrence E. Ashery Robert L. Andersen Christopher R. Lewis Louis W. Beardell, Jr. Rocco L. Adornato Jacques L. Etkowicz Eric A. Dichter	Reg.No. 34,515 Reg.No. 25,771 Reg.No. 36,201 Reg.No. 40,506 Reg.No. 40,480 Reg.No. 41,738 Reg.No. 41,708	Mark J. Marcelli Joshua L. Cohen Christopher J. Dervishian Jack J. Jankovitz	Reg.No. 36,593 Reg.No. 38,040 Reg.No. 42,480 Reg.No. 42,690			
Address all correspondence to: <u>Allan Ratner</u> <u>Ratner & Prestia, Suite 301, One Westlakes, Berwyn, P.O. Box 980, Valley Forge, PA 19482-0980</u> Address all telephone calls to: <u>Allan Ratner</u> at (610) 407-0700.								
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.								
Full name of sole or first inventor (given name, family name) BURCHELL, Brian								
Inventor's signature N/S Residence 8 Dougall Street, Tayport, Fife DD6 9 JB GREAT BRITAIN Citizenship GB Post Office Address 8 Dougall Street Tayport, Fife DD6 9 JB GREAT BRITAIN								
Full name of second joint inventor, if any (given name, family name)								
Second Inventor's signature Date Residence Citizenship Post Office Address								
Additional inventors are being named on separately numbered sheets attached hereto.								